Recce Pharmaceuticals secures patent for RECCE® anti-infectives in Israel

Recce Pharmaceuticals Limited (ASX: $RCE) has announced the formal granting of Patent Number 295116, 'Process for Preparation of Biologically Active Copolymer Comprising an Acrolein Derivative and a Polyalkylene Glycol Oligomer' in Israel, marking the first of Recce's wholly owned patents Granted in Israel. The patent claims relate to RECCE® 327 (R327) and RECCE® 529 (R529), covering processes for preparation and use in the treatment of bacterial and viral infections, further validating RECCE® anti-infectives from studies in various conditions. The Chief Executive Officer, James Graham, expressed excitement about advancing the anti-infective portfolio and supporting the Company's Israeli opportunities.

Executive Commentary on Israel Patent Grant

Chief Executive Officer, James Graham said: 'We are thrilled to have received this newly Granted patent in Israel. This patent is a welcomed addition to our intellectual property portfolio, in a region with a well-established reputation for its world-class facilities, broad international reach and market value reaching USD $5.3 billion in 2021. We are excited to continue advancing our anti-infective portfolio supporting the Company's Israeli opportunities over the time ahead.'

Summary of RECCE® anti-infectives patent grant in Israel

Recce Pharmaceuticals Limited (ASX: $RCE) has been granted a new patent in Israel, further strengthening its intellectual property portfolio. The patent covers processes for preparation and use of RECCE® 327 (R327) and RECCE® 529 (R529) in the treatment of bacterial and viral infections. The Company's Chief Executive Officer, James Graham, expressed enthusiasm for the opportunities in Israel's pharmaceutical market, which is predicted to see growth due to the increasing burden of chronic diseases and the expanding elderly population. This patent grant marks a significant milestone for Recce Pharmaceuticals as it continues to advance its anti-infective portfolio and pursue opportunities in Israel.